{"prompt": "['NET-PRO Protocol v1.3', 'April 2022', 'were non-Hispanic white race (83% rural vs 64% urban). There were also higher proportions of advanced', 'stage disease (regional vs distant metastases) in rural versus urban patients [57].', 'The baseline demographic characteristics of NET patients in this planned PCORnet study are relatively', 'consistent with those previously reported in population-based registries. As can be seen in Table 9,', 'across the 14 participating PCORnet datamarts in our planned prospective cohort analysis (including', '4', \"geographically dispersed CRN's STAR, OneFlorida, GPC and PATH), the majority of patients we will\", 'recruit will be non-Hispanic white (2595/3010 or 86%). Whilst this proportion is perhaps higher than', 'what would be expected nationally, it is not dissimilar from the 86% Caucasian NET population (mean', 'age 56 years) observed in an earlier analysis of 7 National Comprehensive Cancer Network institutions', '[58], which is perhaps not surprising given 12 out of our 14 PCORnet partners are affiliated with an NCI-', 'designated comprehensive Cancer Center and many include a rural catchment area. Women and men', 'will be recruited into the study in proportion to their frequency in the affected patient groups. This', 'means that slightly more women will be recruited than men. We will work with our affiliated CTSAs and', 'NCI-designated cancer center clinical research cores to implement rigorous coordination and navigation', 'support to encourage participation by disadvantaged individuals. It is our intention to also enroll NET', 'patients through our established five NET patient advocacy organizations across North America to boost', 'the ethnic diversity of the NET patients our cohort will likely enroll.', 'Table 9: Estimated Final Racial/Ethnic and Gender Enrollment Table', 'Race', 'Male (N)', 'Female (N)', 'Total (N)', 'American Indian/Alaska Native', '-', '-', '-', 'Asian', '6', '8', '14', 'Black/African American', '135', '159', '294', 'Hawaiian/Pacific Islander', '-', '-', '-', 'White', '1194', '1401', '2595', 'Multirace', '-', '-', '-', 'Other', '49', '58', '107', 'Ethnicity', 'Male (N)', 'Female (N)', 'Total (N)', 'Hispanic (Latino/Latina)', '41', '49', '90', 'Non-Hispanic', '1343', '1577', '2920', '59']['NET-PRO Protocol v1.3', 'April 2022', 'REFERENCES', '1.', 'Dasari, A., et al., Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With', 'Neuroendocrine Tumors in the United States. JAMA Oncol, 2017. 3(10): p. 1335-1342.', '2.', 'Grozinsky-Glasberg, S., A.B. Grossman, and M. Korbonits, The role of somatostatin analogues in', 'the treatment of neuroendocrine tumours. Mol Cell Endocrinol, 2008. 286(1-2): p. 238-50.', '3.', 'Darba, J. and A. Marsa, Exploring the current status of neuroendocrine tumours: a population-', 'based analysis of epidemiology, management and use of resources. BMC Cancer, 2019. 19(1): p.', '1226.', '4.', 'Oronsky, B., et al., Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.', 'Neoplasia, 2017. 19(12): p. 991-1002.', '5.', 'Halperin, D.M., et al., Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a', 'population-based study. Lancet Oncol, 2017. 18(4): p. 525-534.', '6.', 'Martini, C., et al., Systematic review reveals lack of quality in reporting health-related quality of', 'life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life', 'Outcomes, 2016. 14(1): p. 127.', '7.', 'Jim\u00e9nez-Fonseca, P., et al., Health-related quality of life in well-differentiated metastatic', 'gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev, 2015. 34(3): p. 381-400.', '8.', 'Beaumont, J.L., et al., Comparison of health-related quality of life in patients with', 'neuroendocrine tumors with quality of life in the general US population. Pancreas, 2012. 41(3):', 'p. 461-6.', '9.', 'Haugland, T., et al., Health related quality of life in patients with neuroendocrine tumors', 'compared with the general Norwegian population. Qual Life Res, 2009. 18(6): p. 719-26.', '10.', 'Ramage, J.K., et al., Observational Study to Assess Quality of Life in Patients with Pancreatic', 'Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV', 'Trial). Neuroendocrinology, 2019. 108(4): p. 317-327.', '11.', 'Singh, S., et al., Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results', 'From the First Global Survey of Patients With NETs. J Glob Oncol, 2017. 3(1): p. 43-53.', '12.', 'Leyden, S., et al., Unmet needs in the international neuroendocrine tumor (NET) community:', 'Assessment of major gaps from the perspective of patients, patient advocates and NET health', 'care professionals. Int J Cancer, 2020. 146(5): p. 1316-1323.', '13.', 'Hallet, J., et al., Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based', 'Analysis of Prospective Patient-Reported Outcomes. Oncologist, 2019. 24(10): p. 1384-1394.', '14.', 'WHO, WHO classification of tumours of endocrine organs. 4th ed, ed. L. RV, K. G, and R. J. Vol.', '10. 2017, Lyon.', '15.', 'Rindi, G., et al., A common classification framework for neuroendocrine neoplasms: an', 'International Agency for Research on Cancer (IARC) and World Health Organization (WHO)', 'expert consensus proposal. Mod Pathol, 2018. 31(12): p. 1770-1786.', '16.', 'Coriat, R., et al., Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors:', 'Review and Position Statement. Oncologist, 2016. 21(10): p. 1191-1199.', '17.', 'Uri, I. and S. Grozinsky-Glasberg, Current treatment strategies for patients with advanced', 'gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol, 2018. 4:', 'p. 16.', '18.', 'Caplin, M.E., et al., Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine', 'Tumor Society expert consensus and recommendations for best practice for typical and atypical', 'pulmonary carcinoids. Ann Oncol, 2015. 26(8): p. 1604-20.', '19.', 'Garcia-Carbonero, R., et al., ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic', 'Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology, 2016. 103(2): p.', '186-94.', '60']\n\n###\n\n", "completion": "END"}